Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):539-541. doi: 10.1016/j.clml.2017.06.032. Epub 2017 Jun 30.

Authors

Catherine Tang¹, Julian Lindsay², Anthony Gill³, Ian Kerridge²

Affiliations

¹ Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic address: catherine.tang2@health.nsw.gov.au.
² Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
³ Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

PMID: 28842141
DOI: 10.1016/j.clml.2017.06.032

No abstract available

Keywords: Defibrotide; Diffuse Large B cell Lymphoma; Hepatotoxicity; Veno-occlusive disease; Vincristine.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Phytogenic / adverse effects*
Biomarkers
Biopsy
Fibrinolytic Agents / therapeutic use*
Hepatic Veno-Occlusive Disease / diagnosis
Hepatic Veno-Occlusive Disease / drug therapy*
Hepatic Veno-Occlusive Disease / etiology*
Humans
Lymphoma, Large B-Cell, Diffuse / complications
Lymphoma, Large B-Cell, Diffuse / drug therapy
Male
Polydeoxyribonucleotides / therapeutic use*
Treatment Outcome
Vincristine / adverse effects*

Substances

Antineoplastic Agents, Phytogenic
Biomarkers
Fibrinolytic Agents
Polydeoxyribonucleotides
defibrotide
Vincristine